GSK To Invest Approximately $360 Million at Three UK Manufacturing SitesBy
GlaxoSmithKline (GSK) plans to invest Â£275 million ($362 million) at three of its manufacturing sites in the UK to boost production and support delivery of respiratory and biological medicines. The vast majority of these products will be for export to global markets.
The investment is split across three UK sites. At its secondary manufacturing site in Barnard Castle, County Durham, the company is investing Â£92 million ($121 million) to construct an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets in the company’s pipeline. The Barnard Castle is one of GSK's biggest secondary manufacturing sites, employing 1,100 people. The site supplies nearly half a million packs of products per day to 140 global markets.
GSK is also investing Â£110 million ($145 million) for a new manufacturing facility for producing active ingredients for respiratory products at it site in Montrose in Angus in Scotland. The site manufactures active ingredients for respiratory, HIV, and vaccine products and employs over 450 staff.
The company is also investing Â£74 million ($97 million) to expand manufacturing capacity at it site in Ware in Hertfordshire, UK for the company's new Ellipta respiratory inhaler. The Ware site, which manufacturers respiratory products, employs approximately 1,200 staff.
Overall, GSK has nine manufacturing sites in the UK that employ approximately 6,000 people.